Hansoh Pharmaceutical (03692): Aumolertinib Marketing Authorization Receives Positive Opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use

Zhitong Finance APP news, Hansoh Pharmaceutical (03692) announced that on November 12, 2026, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of marketing authorization for almonertinib for the treatment of non-small cell lung cancer.